FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug

Thumbnail
2021
In_vitro-in_vivo_pub_2021.pdf (1.967Mb)
Authors
Shi, Changzhi
Ignjatović, Jelisaveta
Liu, Tingting
Han, Meihua
Cun, Dongmei
Đuriš, Jelena
Yang, Mingshi
Cvijić, Sandra
Article (Published version)
Metadata
Show full item record
Abstract
This study aims to understand the absorption patterns of three different kinds of inhaled formulations via in silico modeling using budesonide (BUD) as a model drug. The formulations investigated in this study are: (i) commercially available micronized BUD mixed with lactose (BUD-PT), (ii) BUD nanocrystal suspension (BUD-NC), (iii) BUD nanocrystals embedded hyaluronic acid microparticles (BUD-NEM). The deposition patterns of the three inhaled formulations in the rats’ lungs were determined in vivo and in silico predicted, which were used as inputs in GastroPlus™ software to predict drug absorption following aerosolization of the tested formulations. BUD pharmacokinetics, estimated based on intravenous data in rats, was used to establish a drug-specific in silico absorption model. The BUD-specific in silico model revealed that drug pulmonary solubility and absorption rate constant were the key factors affecting pulmonary absorption of BUD-NC and BUD-NEM, respectively. In the case of BUD...-PT, the in silico model revealed significant gastrointestinal absorption of BUD, which could be overlooked by traditional in vivo experimental observation. This study demonstrated that in vitro-in vivo-in silico approach was able to identify the key factors that influence the absorption of different inhaled formulations, which may facilitate the development of orally inhaled formulations with different drug release/absorption rates.

Keywords:
Budesonide / In silico physiologically-based pharmacokinetic modeling / Nanocrystal suspension / Nanocrystal-embedded microparticles / Pulmonary drug delivery
Source:
Asian Journal of Pharmaceutical Sciences, 2021, 16, 3, 350-362
Publisher:
  • Elsevier B.V.
Funding / projects:
  • Ministry of Education, Science and Technological Development, Republic of Serbia, Grant no. 200161 (University of Belgrade, Faculty of Pharmacy) (RS-200161)
  • National Natural Science Foundation of China (Nos.81302720 and No.81573380)
  • European Cooperation in Science and Technology

DOI: 10.1016/j.ajps.2020.12.001

ISSN: 1818-0876

WoS: 000669676300008

Scopus: 2-s2.0-85102878238
[ Google Scholar ]
4
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/3902
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Shi, Changzhi
AU  - Ignjatović, Jelisaveta
AU  - Liu, Tingting
AU  - Han, Meihua
AU  - Cun, Dongmei
AU  - Đuriš, Jelena
AU  - Yang, Mingshi
AU  - Cvijić, Sandra
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3902
AB  - This study aims to understand the absorption patterns of three different kinds of inhaled formulations via in silico modeling using budesonide (BUD) as a model drug. The formulations investigated in this study are: (i) commercially available micronized BUD mixed with lactose (BUD-PT), (ii) BUD nanocrystal suspension (BUD-NC), (iii) BUD nanocrystals embedded hyaluronic acid microparticles (BUD-NEM). The deposition patterns of the three inhaled formulations in the rats’ lungs were determined in vivo and in silico predicted, which were used as inputs in GastroPlus™ software to predict drug absorption following aerosolization of the tested formulations. BUD pharmacokinetics, estimated based on intravenous data in rats, was used to establish a drug-specific in silico absorption model. The BUD-specific in silico model revealed that drug pulmonary solubility and absorption rate constant were the key factors affecting pulmonary absorption of BUD-NC and BUD-NEM, respectively. In the case of BUD-PT, the in silico model revealed significant gastrointestinal absorption of BUD, which could be overlooked by traditional in vivo experimental observation. This study demonstrated that in vitro-in vivo-in silico approach was able to identify the key factors that influence the absorption of different inhaled formulations, which may facilitate the development of orally inhaled formulations with different drug release/absorption rates.
PB  - Elsevier B.V.
T2  - Asian Journal of Pharmaceutical Sciences
T1  - In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug
VL  - 16
IS  - 3
SP  - 350
EP  - 362
DO  - 10.1016/j.ajps.2020.12.001
ER  - 
@article{
author = "Shi, Changzhi and Ignjatović, Jelisaveta and Liu, Tingting and Han, Meihua and Cun, Dongmei and Đuriš, Jelena and Yang, Mingshi and Cvijić, Sandra",
year = "2021",
abstract = "This study aims to understand the absorption patterns of three different kinds of inhaled formulations via in silico modeling using budesonide (BUD) as a model drug. The formulations investigated in this study are: (i) commercially available micronized BUD mixed with lactose (BUD-PT), (ii) BUD nanocrystal suspension (BUD-NC), (iii) BUD nanocrystals embedded hyaluronic acid microparticles (BUD-NEM). The deposition patterns of the three inhaled formulations in the rats’ lungs were determined in vivo and in silico predicted, which were used as inputs in GastroPlus™ software to predict drug absorption following aerosolization of the tested formulations. BUD pharmacokinetics, estimated based on intravenous data in rats, was used to establish a drug-specific in silico absorption model. The BUD-specific in silico model revealed that drug pulmonary solubility and absorption rate constant were the key factors affecting pulmonary absorption of BUD-NC and BUD-NEM, respectively. In the case of BUD-PT, the in silico model revealed significant gastrointestinal absorption of BUD, which could be overlooked by traditional in vivo experimental observation. This study demonstrated that in vitro-in vivo-in silico approach was able to identify the key factors that influence the absorption of different inhaled formulations, which may facilitate the development of orally inhaled formulations with different drug release/absorption rates.",
publisher = "Elsevier B.V.",
journal = "Asian Journal of Pharmaceutical Sciences",
title = "In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug",
volume = "16",
number = "3",
pages = "350-362",
doi = "10.1016/j.ajps.2020.12.001"
}
Shi, C., Ignjatović, J., Liu, T., Han, M., Cun, D., Đuriš, J., Yang, M.,& Cvijić, S.. (2021). In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug. in Asian Journal of Pharmaceutical Sciences
Elsevier B.V.., 16(3), 350-362.
https://doi.org/10.1016/j.ajps.2020.12.001
Shi C, Ignjatović J, Liu T, Han M, Cun D, Đuriš J, Yang M, Cvijić S. In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug. in Asian Journal of Pharmaceutical Sciences. 2021;16(3):350-362.
doi:10.1016/j.ajps.2020.12.001 .
Shi, Changzhi, Ignjatović, Jelisaveta, Liu, Tingting, Han, Meihua, Cun, Dongmei, Đuriš, Jelena, Yang, Mingshi, Cvijić, Sandra, "In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug" in Asian Journal of Pharmaceutical Sciences, 16, no. 3 (2021):350-362,
https://doi.org/10.1016/j.ajps.2020.12.001 . .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB